Abstract 19294: A Physical Activity Intervention Improves 400-Meter Walking Velocity as Compared to a Successful Aging Intervention in Patients with Peripheral Artery Disease: The LIFE Study Randomized Trial
Background: The LIFE Study was a multi-centered randomized trial that compared the ability of a structured physical activity (PA) intervention vs. a successful aging intervention (SA) to prevent mobility disability in older sedentary people. In exploratory analyses, we compared the ability of the PA vs. the SA intervention to improve 400 meter walking velocity among participants with and without peripheral artery disease (PAD), respectively.
Methods: Sedentary people age 70-89 were randomized to PA vs. SA. The PA intervention consisted of a structured moderate intensity physical activity program, with aerobic and resistance exercises. PA participants exercised five days weekly, with two sessions per week on site. The SA intervention consisted of weekly health education sessions for six months, followed by monthly education sessions. The ankle brachial index (ABI) and 400-meter walk were measured at baseline. 400-meter walk was repeated every six-months. We report mean 400-meter walking velocity during follow-up in the PA and SA groups, according to baseline ABI. Results adjust for baseline walking velocity, site, and sex.
Results: Of 1,635 LIFE participants, 1,567 (96%) had an ABI measurement of < 1.40 at baseline. Of these, 472 (30%) had ABI < 0.99 and 508 (32%) had ABI 1.00-1.09. Overall, mean age was 78.9 years. Participants included 67.2% females and 17.6% African-Americans. Mean follow-up was 2.6 years. 400-meter walking velocity improved in participants with low ABI (ABI < 0.99) (P=0.003) and borderline ABI (ABI 1.00-1.09) (P=0.017), but not in those with normal ABI (P=0.814) [p-value for interaction: 0.063]. Results (means (standard deviation)) by ABI category are shown in the Table.
Conclusions: Among LIFE Study participants, 400-meter walking velocity improved in response to a physical activity intervention among participants with PAD or borderline low ABI but not among those with a normal baseline ABI.
Author Disclosures: M. McDermott: None. D. Bonds: None. T. Buford: None. T. Church: None. J. Dodson: None. R. Fielding: Other; Modest; Cytokinetics, Pfizer, Ammonett, Myosyntax, Regeneron, Nestle. Other; Significant; Segterra, Pronutria. J. Guralnik: None. S. Kritchevsky: None. L. Lovato: None. M. Pahor: None. R. Stafford: None. A. Newman: None.
- © 2014 by American Heart Association, Inc.